John W Steinke1, Larry Borish. 1. Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA.
Abstract
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is explained in part by overexpression of 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes (CysLTs) and driving the surge in CysLT production that occurs with aspirin ingestion. Similarly, AERD is characterized by the overexpression of CysLT receptors. Increased levels of both interleukin (IL)-4 and interferon (IFN)-γ are present in the tissue of AERD subjects. Previous studies demonstrated that IL-4 is primarily responsible for the up-regulation of LTC4S by mast cells. METHODS: Literature review. RESULTS: Our previous studies demonstrated that IFN-γ, but not IL-4, drives this process in eosinophils. These published studies also extend to both IL-4 and IFN-γ the ability to up-regulate CysLT receptors. Prostaglandin E2 (PGE2) acts to prevent CysLT secretion by inhibiting mast cell and eosinophil activation. PGE2 concentrations are reduced in AERD, and our published studies confirm that this reflects diminished expression of cyclooxygenase (COX)-2. A process again that is driven by IL-4. Thus, IL-4 and IFN-γ together play an important pathogenic role in generating the phenotype of AERD. Finally, induction of LTC4S and CysLT1 receptors by IL-4 reflects in part the IL-4-mediated activation of signal transducer and activator of transcription 6 (STAT6). Our previous studies demonstrated that aspirin blocks trafficking of STAT6 into the nucleus and thereby prevents IL-4-mediated induction of these transcripts, thereby suggesting a modality by which aspirin desensitization could provide therapeutic benefit for AERD patients. CONCLUSION: This review will examine the evidence supporting this model.
BACKGROUND:Aspirin-exacerbated respiratory disease (AERD) is explained in part by overexpression of 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes (CysLTs) and driving the surge in CysLT production that occurs with aspirin ingestion. Similarly, AERD is characterized by the overexpression of CysLT receptors. Increased levels of both interleukin (IL)-4 and interferon (IFN)-γ are present in the tissue of AERD subjects. Previous studies demonstrated that IL-4 is primarily responsible for the up-regulation of LTC4S by mast cells. METHODS: Literature review. RESULTS: Our previous studies demonstrated that IFN-γ, but not IL-4, drives this process in eosinophils. These published studies also extend to both IL-4 and IFN-γ the ability to up-regulate CysLT receptors. Prostaglandin E2 (PGE2) acts to prevent CysLT secretion by inhibiting mast cell and eosinophil activation. PGE2 concentrations are reduced in AERD, and our published studies confirm that this reflects diminished expression of cyclooxygenase (COX)-2. A process again that is driven by IL-4. Thus, IL-4 and IFN-γ together play an important pathogenic role in generating the phenotype of AERD. Finally, induction of LTC4S and CysLT1 receptors by IL-4 reflects in part the IL-4-mediated activation of signal transducer and activator of transcription 6 (STAT6). Our previous studies demonstrated that aspirin blocks trafficking of STAT6 into the nucleus and thereby prevents IL-4-mediated induction of these transcripts, thereby suggesting a modality by which aspirin desensitization could provide therapeutic benefit for AERD patients. CONCLUSION: This review will examine the evidence supporting this model.
Authors: Kimberly Mascia; Tmirah Haselkorn; Yamo M Deniz; Dave P Miller; Eugene R Bleecker; Larry Borish Journal: J Allergy Clin Immunol Date: 2005-10-03 Impact factor: 10.793
Authors: Kimberly Mascia; Larry Borish; James Patrie; John Hunt; C Douglas Phillips; John W Steinke Journal: Ann Allergy Asthma Immunol Date: 2005-06 Impact factor: 6.347
Authors: Lisa A Spencer; Rossana C N Melo; Sandra A C Perez; Staci P Bafford; Ann M Dvorak; Peter F Weller Journal: Proc Natl Acad Sci U S A Date: 2006-02-21 Impact factor: 11.205
Authors: Sun Ying; Qiu Meng; Glenis Scadding; Abhi Parikh; Chris J Corrigan; Tak H Lee Journal: J Allergy Clin Immunol Date: 2006-02 Impact factor: 10.793
Authors: Whitney W Stevens; Anju T Peters; Annemarie G Hirsch; Cara M Nordberg; Brian S Schwartz; Dione G Mercer; Mahboobeh Mahdavinia; Leslie C Grammer; Kathryn E Hulse; Robert C Kern; Pedro Avila; Robert P Schleimer Journal: J Allergy Clin Immunol Pract Date: 2017-03-09
Authors: Kavita Pal; Madison Ramsden; Yun M Shim; Larry Borish; Spencer C Payne; John W Steinke Journal: Ann Allergy Asthma Immunol Date: 2019-09-09 Impact factor: 6.347